Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment

Mild Cognitive Impairment Clinical Trial

Official title:

Phase I/II Randomized Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05480358
• Other study ID #: FMD AD
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 1, 2019
• Est. completion date: August 2023

Study information

• Verified date: July 2022
• Source: University of Genova
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The wide-acting effects of Fasting-Mimicking Diets (FMDs) on metabolic, inflammatory and regenerative pathways leading to reduced pathology or risk factors for various diseases in mice and humans, has the potential to be effective against Alzheimer's disease (AD). It is proposed to conduct a randomized clinical trial of twelve monthly cycles of the ProlonADTM diet (by L-Nutra) vs. placebo diet in patients with aMCI or mild AD (MMSE 18-23). The primary endpoint of the study will be the feasibility and safety of the twelve cycles of ProlonADTM.

Description:

Cognitive impairment that exceeds the physiological decline associated with aging can take the form of mild cognitive impairment (MCI) or, in its most severe form, dementia. In turn, patients diagnosed with MCI evolve towards outright Alzheimer's disease (AD) in an estimated percentage of 15%/year. MCI can occur in the form of amnestic MCI (amnestic MCI, aMCI; by far the most common) or non-amnestic MCI (single or multiple domain), where amnestic is the form that most frequently evolves into AD. Therefore this clinical trial will focus on the latter (as well as on the AD). Diet cycles with low sugar and protein levels followed by diets with normal levels of these lead to temporary reductions in growth hormone and IGF-1 levels. Both are potential mediators of the neuroprotective and regenerative effects of these diets not only in mice, but also in monkeys and humans . However, heavily restricted diets in terms of calories are often difficult to endure over time and are frequently associated with side effects, even significant ones and with progressive weight loss, in particular of lean mass. In a mouse model of AD, it has been shown that periodic cycles of a "fasting-mimicking" diet (FMD) restricted in protein content (PR-FMD) but not in terms of calories are able to reduce levels plasma levels of IGF-1 with contrasting effects on the neurodegeneration process. In particular, such FMD has been shown to reduce by about 30-70%, the levels of hyperphosphorylated tau protein (one of the typical markers of AD) at the hippocampal level, reducing the age-related deficit of cognitive performance. A relevant neuroregenerative effect (associated with a clinical improvement in motor coordination and memory) has been demonstrated in mice subjected to a diet based on a similar DMD during their "average life" (months 16-30).

It is proposed to conduct a study of twelve monthly cycles of the ProlonADTM diet (by L-Nutra) in patients with aMCI or mild AD (MMSE 18-23) diagnosed according to the criteria defined by Peterson and McKahn, respectively (1, 3 ).

It is proposed to conduct a randomized clinical trial of twelve monthly cycles of the ProlonADTM diet (by L-Nutra) vs. placebo diet in patients with aMCI or mild AD (MMSE 18-23). Patients in the treatment group alone will also receive a range of supplements containing omega-3 fatty acids, caffeine, tree nuts, coconut oil, olive oil and cocoa - which will be supplied with the ProlonADTM diet kit. Patients assigned to both arms will also receive personalized dietary recommendations matched to instructions for light-moderate physical activity to be carried out also at home and aimed, especially in the case of patients assigned to receive ProlonADTM, to prevent the loss of lean mass. The primary endpoint of the study will be the feasibility and safety of the twelve cycles of ProlonADTM. Feasibility is defined as taking at least one course of DMD every two months with the option of admitting consumption of 50% of the planned diet and / or a maximum consumption of 10 Kcal / kg of unforeseen food in only one of days 1-5 of each cycle. Investigators speculate that ProlonADTM will not cause severe side effects and that it will have no detrimental effect on the patient's body composition, specifically in terms of impact on lean mass measured by dynamometry and bioimpedance analysis.

Secondary objectives will include:

• conversion rate to AD (for patients with aMCI);

• episodic memory evaluated with Free and Cued Selective Reminding Test (FCRST);

• cognitive status assessed by MMSE, CDR-Sum of the boxes;

• functional status assessed with Barthel Index, IADL;

• emotional state assessed using the CESD-R scale;

• nutritional status (MNA and body composition - bioimpedance, handgrip);

• caregiver stress assessed through Caregiver Burden Inventory and NPI;

• quality of life of patients (QLQ-AD);

• inflammatory markers, oxidative stress markers, neuronal damage markers (Neurofilament Light, NfL), quantification of circulating stem cells, cell aging markers (eg evaluation of the telomerase activity of lymphocytes).

• assessment of frailty (Rockwood frailty index, which also includes walking speed, handgrip, breathing capacity)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: August 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age 55-80;

• Presence of aMCI or initial AD (MMSE 18-23);

• Normal organ function (liver and kidney);

• BMI not less than 20 kg/m2;

• Bioimpedance phase angle (PA) > 5 °;

• Adherence to informed consent

Exclusion Criteria:

• Age> 80 years

• Diabetes mellitus;

• Organ impairment (liver, kidney);

• Food allergies to the components of ProlonADTM;

• Patients on therapy with vitamin K antagonist anticoagulants;

• PA <5 °;

• Patients who live alone or are not adequately supported by the family context;

• Other experimental therapies in progress.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment
• Mild Dementia

Intervention

Dietary Supplement:
• Fasting-Mimicking Diet ProlonADTM
Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.

Locations

Country	Name	City	State
Italy	Alessio Nencioni	Genoa	GE
Italy	Ospedale Policlinico San Martino	Genova
Italy	Azienda Ospedaliera di Perugia	Perugia

Sponsors (1)

Lead Sponsor	Collaborator
University of Genova

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events	Safety of FMD in terms of percentage of patients experiencing adverse events and/or worsening of nutritional status.; To obtain clinical data on safety of the FMD in MCI or AD patients as assessed by percentage of patients (%) experiencing > grade 3 adverse events and/or a significant decrease in their lean body mass (kg) and/or with a reduction of phase angle <5° assessed with bio-impedance measurements.	12 months
Primary	Percentage of patients able to achieve the designated diet regimen	Feasibility of FMD in terms of percentage of patients able to complete the diet regimen To evaluate the feasibility of the FMD in MCI and AD patients as assessed by the percentage of patients (%) able to achieve the designated diet regimen.	12 months
Secondary	Efficacy of the FMD in terms of conversion rate to AD	Efficacy of the FMD in terms of coversion rate to AD will be assessed with the conversion rate (%) from AD to aMCI	12 months
Secondary	Efficacy of the FMD in terms of functional state	Efficacy of the FMD in terms of functional will be assessed with Barthel Index (BI) from 0 as the worse score and 100 as the best score.	12 months
Secondary	Efficacy of the FMD in terms of emotional state	Efficacy of the FMD in terms of emotional state will be assessed with the Center for Epidemiologic Studies Depression Scale Revised (CESD-R) with 0 as the best score and 80 as the worse score.	12 months
Secondary	Efficacy of the FMD in terms of nutritional state	Efficacy of the FMD in terms of nutritional state will be assessed with phase angle with bioimpedance (°)	12 months
Secondary	Efficacy of the FMD in terms of caregiver stress' level	Caregiver stress will assessed through Caregiver Burden Inventory (CBI) with 0 as the best score and 96 as the worse score	12 months
Secondary	Efficacy of the FMD in terms of quality of life	Efficacy of the FMD in terms of quality of life of patients with Quality of Life AD (QLQ-AD) with 13 as the worse score and 52 as the best score.	12 months
Secondary	Efficacy of the FMD in terms of prevention of Frailty	Efficacy of the FMD in terms of prevention of Frailty with 40-item Rockwood frailty index (FI) with 0 as the best score and 1 as the worse score.	12 months
Secondary	Efficacy of the FMD in terms of alzheimer and inflammatory biomarkers	We will assess the inflammatory markers, oxidative stress markers, neuronal damage markers (Neurofilament Light, NfL), quantification of circulating stem cells, cell aging markers (eg evaluation of the telomerase activity of lymphocytes)	12 months
Secondary	Efficacy of the FMD in terms of episodic memory	Efficacy of the FMD in terms of episodic memory will evaluated with Free and Cued Selective Reminding Test (FCRST) with a range from 0 as worse score to 36 as best score.	12 months
Secondary	Efficacy of the FMD in terms of general cognitive status	Efficacy of the FMD in terms of general cognitive status with mini-mental state examination (MMSE) with 0 as worse score and 30 as the best score.	12 months